← All trials
NCT04810754
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2021
- Primary completion
- Mar 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Mar 23, 2021
- Last posted
- Mar 23, 2021
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Humboldt UniversityLead sponsor
- Johnson and JohnsonCollaborator
- Humboldt UniversityReponsible party - principal investigator
- Humboldt UniversityOverall official - principal investigator
- Humboldt UniversityCollaborator
- Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)Collaborator
- Charité University, Berlin, GermanyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.